Advances in lopinavir formulations: strategies to overcome solubility, bioavailability, and stability challenges

ANAND REDDY SINGIREDDY; Sobitha Rani Pedireddi

doi:10.56782/pps.280

Published : 2024-12-24

Vol. 22 No. 4 (2024)

Advances in lopinavir formulations: strategies to overcome solubility, bioavailability, and stability challenges

Dr Singireddy Anand Reddy

Dr Sobitha Rani

DOI: https://doi.org/10.56782/pps.280

Abstract

Lopinavir, a key protease inhibitor in antiretroviral therapy, faces significant challenges related to its poor solubility, low bioavailability, and low stability, which limit its therapeutic efficacy. This review explores a range of advanced formulation strategies developed to overcome these limitations, enhancing lopinavir’s delivery and effectiveness. Nanoparticle-based systems such as solid lipid nanoparticles, nanostructured lipid carriers, and lipid-polymer hybrid systems demonstrate notable improvements in bioavailability, drug release, and lymphatic targeting. Additionally, solid dosage formulations like amorphous solid dispersions and proliposomes have been shown to significantly enhance solubility and stability, improving lopinavir’s pharmacokinetic profile. By reviewing the preparation techniques, in vivo results, and comparative advantages of these innovative delivery systems, this article provides insight into their potential to optimize lopinavir-based therapies. Furthermore, the review discusses the role of these strategies in addressing adherence issues, ultimately improving patient outcomes. Continued research into the novel approaches is essential for advancing lopinavir delivery and enhancing its clinical efficacy in the treatment of HIV.

Keywords:

Antiretroviral therapy, Drug delivery systems, Bioavailability, HIV treatment, Pharmacokinetics

Similar Articles

Angelika Lis, Katarzyna Wyszomierska, Katarzyna Znajdek, Łukasz Szeleszczuk, Monika Zielińska-Pisklak, PHOTOSENSITIVITY PHENOMENON – A SIGNIFICANT ADVERSE EFFECT OF COMMONLY USED DRUGS , Prospects in Pharmaceutical Sciences: Vol. 19 No. 3 (2021)
Bartosz Kózka, Karolina Bębas, POZOSTAŁOŚCI SUBSTANCJI FARMAKOLOGICZNIE CZYNNYCH JAKO ZANIECZYSZCZENIE ŚRODOWISKA I ROLA GRZYBÓW BIAŁEJ ZGNILIZNY W ICH USUWANIU , Prospects in Pharmaceutical Sciences: Vol. 19 No. 5 (2021)
Aleksandra Grzybowska, Tomasz Lorenc, Wioletta Olejarz, Grażyna Nowicka, EXOSOMES AS CARRIERS OF INFORMATION BEETWEN TUMOR CELLS , Prospects in Pharmaceutical Sciences: Vol. 17 No. 2 (2019)
Aleksandra Kowalska, The Vitamin E: overview of history of discovery, mechanism of action, role and deficiency , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Aleksandra Białczyk, Gabriela Leśniak, Filip Nadolny, Justyna Mrowiec, Antoni Otałęga, Exploring digital health horizons: a narrative review of e-health innovations in Poland, Spain, Romania and Estonia. , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Grażyna Kubiak-Tomaszewska, Jan Pachecka, Jacek Łukaszkiewicz, Piotr Tomaszewski, MECHANISMS OF RECEPTOR-DEPENDENT REGULATION OF BILE ACID AND XENOBIOTIC METABOLISM. THE ROLE OF CYP3A4 EXPRESSION IN THE SAFETY AND EFFECTIVENESS OF PHARMACOTHERAPY , Prospects in Pharmaceutical Sciences: Vol. 14 No. 9 (2016)
Magdalena Bamburowicz-Klimkowska, Urszula Bogucka, Mirosław M. Szutowski, FUNCTIONS OF ATP-BINDING CASSETTE (ABC) TRANSPORTERS , Prospects in Pharmaceutical Sciences: Vol. 9 No. 3 (2011)
Sylwia Osowska, Joanna Regulska, Lipid peroxidation markers used in parenteral nutrition , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
Wojciech Kaźmierski, Jakub Jurek, Paulina Lis, Anna Lis, Anna Ziobro, Mateusz Ziomek, Katarzyna Camlet, Kinga Kocur, Sodium-glucose cotransporter2 inhibitors in heart failure , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Katarzyna Herjan, Piotr Armański, Jakub Olszewski, Magdalena Sitnik, Maciej Bara, Positive impact of tranexamic acid in various medical settings , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)

<< < 3 4 5 6 7 8 9 10 11 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

SINGIREDDY, A. R., & Pedireddi, S. R. (2024). Advances in lopinavir formulations: strategies to overcome solubility, bioavailability, and stability challenges. Prospects in Pharmaceutical Sciences, 22(4), 105–121. https://doi.org/10.56782/pps.280

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Aronson, J.K. Lopinavir. In Meyler's Side Effects of Drugs (Sixteenth Edition), Elsevier, 2016; pp. 669-675.

2. Eckhardt, B.J.; Gulick, R.M. Drugs for HIV Infection. In Opal, Infectious Diseases, 4th ed.; Jonathan, C., William, G.; Eds.; Elsevier, 2017: pp.1293-1308.

3. Muralidharan, N.; Sakthivel, R.; Velmurugan, D.; Gromiha, M. M. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J. Biomol. Struct. Dyn. 2021, 39(7), 2673-2678.

4. Eche, S.; Kumar, A.; Sonela, N.; Gordon, M.L. Acquired HIV-1 protease conformational flexibility associated with lopinavir failure may shape the outcome of darunavir therapy after antiretroviral therapy switch. Biomolecules 2021, 11(4), Art. No: 489. DOI: 10.3390/biom11040489

5. Mahdi, M.; Mótyán, J.A.; Szojka, Z.I.; Golda, M.; Miczi, M.; Tőzsér, J. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′ s main protease. Virol. J. 2020, 17(190), 1-8. DOI: 10.1186/s12985-020-01457-0

6. Ghosh, A.K.; Osswald, H.L.; Prato, G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. J. Med. Chem. 2016, 59(11), 5172-5208. DOI: 10.1021/acs.jmedchem.5b01697

7. Von der Helm, K. Retroviral proteases: Structure, function and inhibition-from a non-anticipated viral enzyme to the target of a most promising HIV therapy. Biol. Chem. 1996, 377(12), 765-774. DOI: 10.1515/bchm3.1996.377.12.765

8. Ho, W.S.; Zhang, R.; Tan, Y.L.; Chai, C.L. COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt? Pharmacol. Res. 2022, 179, Art. No: 106201. DOI: 10.1016/j.phrs.2022.106201

9. Marin, R.C.; Behl, T.; Negrut, N.; Bungau, S. Management of antiretroviral therapy with boosted protease inhibitors—darunavir/ritonavir or darunavir/cobicistat. Biomedicines 2021, 9(3), Art. No: 313. DOI: 10.3390/biomedicines9030313

10. ter Heine, R.; Van Waterschoot, R.A.; Keizer, R.J.; Beijnen, J.H.; Schinkel, A.H.; Huitema, A.D. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. J. Pharm. Sci. 2011, 100(6), 2508-2515. DOI: 10.1002/jps.22457

11. Kandel, S.E.; Lampe, J.N. Inhibition of CYP3A7 DHEA-S oxidation by lopinavir and ritonavir: an alternative mechanism for adrenal impairment in HIV antiretroviral-treated neonates. Chem. Res. Toxicol. 2021, 34(4), 1150-1160. DOI: 10.1021/acs.chemrestox.1c00028

12. Hul, M.W.; Montaner, J.S. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 2011, 43(5), 375-388. DOI: 10.3109/07853890.2011.572905

13. Juan, C.; Jiang, X.; Qiang, Z. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients. Chin. Med. J. 2014, 127(14), 2632-2636. DOI: 10.3760/cma.j.issn.0366-6999.20140538

14. Lepage, M.A.; Rozza, N.; Kremer, R.; Grunbaum, A. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: A retrospective series. Clin. Toxicol. 2021, 59(7), 644-647. DOI: 10.1080/15563650.2020.1842882

15. Badowski, M.E.; Burton, B.; Shaeer, K.M.; Dicristofano, J. Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use. Drugs. Context. 2019, 8, 1-31. DOI: 10.7573/dic.212550

16. Giacomelli, A.; Pezzati, L.; Rusconi, S. The crosstalk between antiretrovirals pharmacology and HIV drug resistance. Expert. Rev. Clin. Pharmacol. 2020, 13(7), 739-760. DOI: 10.1080/17512433.2020.1782737

17. Nastri, B.M.; Pagliano, P.; Zannella, C.; Folliero, V.; Masullo, A.; Rinaldi, L.; Galdiero, M.; Franci, G. HIV and drug-resistant subtypes. Microorganisms 2023, 11(1), Art. No: 221. DOI: 10.3390/microorganisms11010221

18. Wensing, A.M.; van Maarseveen, N.M.; Nijhuis, M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral. Res. 2010, 85(1), 59-74. DOI: 10.1016/j.antiviral.2009.10.003

19. Su, B.; Wang, Y.; Zhou, R.; Jiang, T.; Zhang, H.; Li, Z.; Liu, A.; Shao, Y.; Hua, W.; Zhang, T.; Wu, H. Efficacy and tolerability of lopinavir/ritonavir-and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front. Pharmacol. 2019, 10, Art. No: 1472. DOI: 10.3389/fphar.2019.01472

20. Gandhi, R.T.; Bedimo, R.; Hoy, J.F.; Landovitz, R.J.; Smith, D.M.; Eaton, E.F.; Lehmann, C.; Springer, S.A.; Sax, P.E.; Thompson, M.A.; Benson, C.A.; Buchbinder, S.P.; Del Rio, C.; Eron Jr, J.J.; Günthard, H.F.; Molina, J.M.; Jacobsen, D.M.; Saag, M.S. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel. JAMA 2023, 329(1), 63-84. DOI: 10.1001/jama.2022.22246

21. Pasley, M.V.; Martinez, M.; Hermes, A.; d'Amico, R.; Nilius, A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS. Rev. 2013, 15(1), 38-48. DOI: 10.1080/15284336.2018.1459343

22. Eggleton, J.S.; Nagalli, S. Highly Active Antiretroviral Therapy (HAART). In: StatPearls [Internet], Eds.; StatPearls: Treasure Island (FL), 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554533/ (accessed 23 September 2024)

23. Hamers, R.L.; de Wit, T.F.; Holmes, C.B. HIV drug resistance in low-income and middle-income countries. Lancet HIV 2018, 5(10), e588-e596. DOI: 10.1016/S2352-3018(18)30173-5

24. Zi, P.; Zhang, C.; Ju, C.; Su, Z.; Bao, Y.; Gao, J.; Sun, J.; Lu, J.; Zhang, C. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant-Soluplus. Eur. J. Pharm. Sci. 2019, 134, 233-245. DOI: 10.1016/j.ejps.2019.04.022

25. Khan, A.A.; Mudassir, J.; Akhtar, S.; Murugaiyah, V.; Darwis, Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics 2019, 11(2), Art. No: 97. DOI: 10.3390/pharmaceutics11020097

26. Angshuman, B.; Bhattacharjee, S.K.; Mahanta, R.; Biswanth, M.; Bandyopadhaya, S.K. Alginate based nanoparticulate drug delivery for anti-HIV drug lopinavir. J. Global. Pharm. Tech. 2010, 2(3), 126-132.

27. Jain, S.; Sharma, J.M.; Jain, A.K.; Mahajan, R.R. Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine 2013, 8(10), 1639-1655. DOI: 10.2217/nnm.12.181

28. Ravi, P.R.; Vats, R.; Balija, J.; Adapa, S.P.; Aditya, N. Modified pullulan nanoparticles for oral delivery of lopinavir: Formulation and pharmacokinetic evaluation. Carbohydr. Polym. 2014, 110, 320-328. DOI: 10.1016/j.carbpol.2014.03.099

29. Ravi, P.R.; Vats, R.; Dalal, V.; Gadekar, N.; Adoitya, N. Design, optimization and evaluation of poly-ɛ-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Drug. Dev. Ind. Pharm. 2015, 41(1), 131-140. DOI: 10.3109/03639045.2013.850710

30. Joshi, G.; Kumar, A.; Sawant, K. Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug. Deliv. 2016, 23(9), 3492-3504. DOI: 10.1080/10717544.2016.1199605.

31. Abou-El-Naga, I.F.; El Kerdany, E.D.; Mady, R.F.; Shalaby, T.I.; Zaytoun, E.M. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitol. Int. 2017, 66(6), 735-747. DOI: 10.1016/j.parint.2017.08.007

32. Liptrott, N.J.; Giardiello, M.; McDonald, T.O.; Rannard, S.P.; Owen, A. Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. Nanomedicine 2017, 12(17), 2043-2054. DOI: 10.2217/nnm-2017-0095

33. Nassar, T.; Rohald, A.; Naraykin, N.; Barasch, D.; Amsalem, O.; Prabhu, P.; Kotler, M.; Benita, S. Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. J. Drug. Target. 2019, 27(5-6), 590-600. DOI: 10.1080/1061186X.2018.1552275

34. Katata-Seru, L.; Ojo, B.M.; Okubanjo, O.; Soremekun, R.; Aremu, O.S. Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories. Heliyon 2020, 6(5), Art. No: e03890. DOI: 10.1016/j.heliyon.2020.e03890

35. Patel, G.; Shelat, P.; Lalwani, A. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment. Drug. Deliv. 2016, 23(8), 3027-3042. DOI: 10.3109/10717544.2016.1141260

36. Khan, A.A.; Akhtar, S.; Yadav, Y.; Atiya, A.; Alelwani, W.; Bannunah, A.M.; Mahmood, S. Lopinavir-Loaded Self-Nanoemulsifying Drug Delivery System for Enhanced Solubility: Development, Characterisation and Caco-2 Cell Uptake. Curr. Drug. Deliv. 2023, 20(10), 1474-1486. DOI: 10.2174/1567201819666220817111054

37. Garg, B.; Katare, O.P.; Beg, S.; Lohan, S.; Singh, B. Systematic development of solid self-nanoemulsifying oily formulations (S-SNEOFs) for enhancing the oral bioavailability and intestinal lymphatic uptake of Lopinavir. Colloids. Surf. B: Biointerfaces 2016, 141, 611-622. DOI: 10.1016/j.colsurfb.2016.02.012

38. Maniyar, M.G.; Kokare, C.R. Formulation and evaluation of spray dried liposomes of lopinavir for topical application. J. Pharm. Investig. 2019, 49, 259-270. DOI: 10.1007/s40005-018-0403-7

39. Patel, K.K.; Kumar, P.; Thakkar, H.P. Formulation of niosomal gel for enhanced transdermal lopinavir delivery and its comparative evaluation with ethosomal gel. AAPS. Pharm. Sci. Tech. 2012, 13, 1502-1510. DOI: 10.1208/s12249-012-9871-7

40. Fayed, N.D.; Essa, E.A.; El Maghraby, G.M. Menthol augmented niosomes for enhanced intestinal absorption of lopinavir. Pharm. Dev. Technol. 2022, 27(9), 956-964. DOI: 10.1080/10837450.2022.2136195

41. Alex, M.A.; Chacko, A.J.; Jose, S.; Souto, E.B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 2011, 42(1-2), 11-18. DOI:10.1016/j.ejps.2010.10.002

42. Alex, A.; Paul, W.; Chacko, A.J.; Sharma, C.P. Enhanced delivery of lopinavir to the CNS using Compritol®-based solid lipid nanoparticles. Ther. Deliv. 2011, 2(1), 25-35. Doi: 10.4155/tde.10.96

43. Negi, J.S.; Chattopadhyay, P.; Sharma, A.K.; Ram, V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur. J. Pharm. Sci. 2013, 48(1-2), 231-239. DOI: 10.1016/j.ejps.2012.10.022

44. Ravi, P.R.; Vats, R.; Dalal, V.; Murthy, A.N. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J. Pharm. Pharmacol. 2014, 66(7), 912-926. DOI: 10.1111/jphp.12217

45. Ravi, P.R.; Vats, R. Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model. J. Pharm. Pharmacol. 2017, 69(7), 823-833. DOI: 10.1111/jphp.12716

46. Ansari, H.; Singh, P. Formulation and in-vivo evaluation of novel topical gel of lopinavir for targeting HIV. Curr. HIV. Res. 2018, 16(4), 270-279. DOI: 10.2174/1570162X16666180924101650

47. Garg, B.; Beg, S.; Kumar, R.; Katare, O.P.; Singh, B. Nanostructured lipidic carriers of lopinavir for effective management of HIV-associated neurocognitive disorder. J. Drug. Deliv. Sci. Tech. 2019, 53, Art. No: 101220. DOI: 10.1016/j.jddst.2019.101220

48. Moura, R.B.; Andrade, L.M.; Alonso, L.; Alonso, A.; Marreto, R.N.; Taveira, S.F. Combination of lipid nanoparticles and iontophoresis for enhanced lopinavir skin permeation: Impact of electric current on lipid dynamics. Eur. J. Pharm. Sci. 2022, 168, Art. No: 106048. DOI: 10.1016/j.ejps.2021.106048

49. Maniyar, M.; Chandak, A.; Kokare, C. Lopinavir loaded spray dried liposomes with penetration enhancers for cytotoxic activity. Infect. Disord. Drug. Targets 2020, 20(5), 724-736. DOI: 10.2174/1871526519666191008112207

50. Hamed, R.; Mohamed, E.M.; Sediri, K.; Khan, M.A.; Rahman, Z. Development of stable amorphous solid dispersion and quantification of crystalline fraction of lopinavir by spectroscopic-chemometric methods. Int. J. Pharm. 2021, 602, Art. No: 120657. DOI: 10.1016/j.ijpharm.2021.120657

51. Li, N.; Taylor, L.S. Microstructure formation for improved dissolution performance of lopinavir amorphous solid dispersions. Mol. Pharm. 2019, 16(4), 1751-1765. DOI: 10.1021/acs.molpharmaceut.9b00117

52. Kasbaum, F.E.; de Carvalho, D.M.; de Jesus Rodrigues, L.; Cardoso, G.; Pinho, L.A.; Martins, F.T.; Cunha-Filho, M.; Taveira, S.F.; Marreto, R.N. Development of lipid polymer hybrid drug delivery systems prepared by hot-melt extrusion. AAPS. Pharm. Sci. Tech. 2023, 24(6), Art. No: 156. DOI: 10.1208/s12249-023-02610-y

53. Kayalar, C.; Helal, N.; Mohamed, E.M.; Dharani, S.; Khuroo, T.; Kuttolamadom, M.A.; Rahman, Z.; Khan, M.A. In Vitro and In Vivo testing of 3D-Printed Amorphous Lopinavir Printlets by Selective Laser Sinitering: Improved Bioavailability of a Poorly Soluble Drug. AAPS. Pharm. Sci. Tech. 2024, 25(1), Art. No: 20. DOI: 10.1208/s12249-023-02729-y

54. Fayed, N.D.; Arafa, M.F.; Essa, E.A.; El Maghraby, G.M. Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption. J. Drug. Deliv. Sci. Technol. 2022, 74, Art. No: 103587. DOI: 10.1016/j.jddst.2022.103587

55. Yun, T.S.; Jung, M.; Bang, K.H.; Lee, H.K.; Jin, M.; Yoo, H.; Won, J.H.; Song, B.; Hwang, Y.R.; Baek, J.S.; Cho, C.W. An economically advantageous amorphous solid dispersion of the fixed combination of lopinavir and ritonavir. J. Pharm. Investig. 2023, 53(4), 549-561. DOI: 10.1007/s40005-023-00623-0

56. Pham, K.; Li, D.; Guo, S.; Penzak, S.; Dong, X. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles. J. Control. Release. 2016, 226, 88-97. DOI: 10.1016/j.jconrel.2016.02.001

57. Else, L.J.; Douglas, M.; Dickinson, L.; Back, D.J.; Khoo, S.H.; Taylor, G.P. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob. Agents Chemother. 2012, 56(2), 816-824. DOI: 10.1128/AAC.05186-11

58. Qin, C.; Chu, Y.; Feng, W.; Fromont, C.; He, S.; Ali, J.; Lee, J.B.; Zgair, A.; Berton, M.; Bettonte, S.; Liu, R. Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. J. Control. Release 2021, 329, 1077-1089. DOI: 10.1016/j.jconrel.2020.10.036

59. Patel, G.M.; Shelat, P.K.; Lalwani, A.N. QbD based development of proliposome of lopinavir for improved oral bioavailability. Eur. J. Pharm. Sci. 2017, 108, 50-61. DOI: 10.1016/j.ejps.2016.08.057

60. Madgulkar, A.R.; Bhalekar, M.R.; Kadam, A.A. Improvement of oral bioavailability of lopinavir without co-administration of ritonavir using microspheres of thiolated xyloglucan. AAPS. Pharm. Sci. Tech. 2018, 19(1), 293-302. DOI: 10.1208/s12249-017-0834-x

61. Patel, D.; Kumar, P.; Thakkar, H.P. Lopinavir metered-dose transdermal spray through microporated skin: Permeation enhancement to achieve therapeutic needs. J. Drug. Deliv. Sci. Tech. 2015, 29, 173-180. DOI: 10.1016/j.jddst.2015.07.004

62. Adeoye, O.; Conceição, J.; Serra, P.A.; da Silva, A.B.; Duarte, N.; Guedes, R.C.; Corvo, M.C.; Aguiar-Ricardo, A.; Jicsinszky, L.; Casimiro, T.; Cabral-Marques, H. Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: In silico prediction; Effects of derivatization, molar ratio and preparation method. Carbohydr. Polym. 2020, 227, Art. No: 115287. DOI: 10.1016/j.carbpol.2019.115287

63. Adeoye, O.; Bártolo, I.; Conceição, J.; da Silva, A.B.; Duarte, N.; Francisco, A.P.; Taveira, N.; Cabral-Marques, H. Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity. Int. J. Pharm. 2020, 583, Art. No: 119356. DOI: 10.1016/j.ijpharm.2020.119356

64. Mahajan, H.S.; Patil, P.H. Central composite design-based optimization of lopinavir vitamin E-TPGS micelle: In vitro characterization and in vivo pharmacokinetic study. Colloids. Surf. B. Biointerfaces 2020, 194, Art. No: 111149. DOI: 10.1016/j.colsurfb.2020.111149

65. Chaudhari, S.P.; Handge, N.M. Formulation, development and evaluation of lopinavir loaded polymeric micelles. J. Sci. Tech. 2020, 5(4), 173-187. DOI: 10.46243/jst.2020.v5.i4.pp173-187

66. Aremu, O.S.; Katata-Seru, L.; Mkhize, Z.; Botha, T.L.; Wepener, V. Polyethylene glycol (5,000) succinate conjugate of lopinavir and its associated toxicity using Danio rerio as a model organism. Sci. Rep. 2020, 10(1), Art. No: 11789. DOI: 10.1038/s41598-020-68666-z

67. Salim, M.; Ramirez, G.; Clulow, A.J.; Hawley, A.; Boyd, B.J. Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy. Mol. Pharmaceutics 2023, 20(4), 2256-2265. DOI: 10.1021/acs.molpharmaceut.3c00072

68. Tanaudommongkon, I.; Tanaudommongkon, A.; Dong, X. Development of in situ self-assembly nanoparticles to encapsulate lopinavir and ritonavir for long-acting subcutaneous injection. Pharmaceutics 2021, 13(6), Art. No: 904. DOI: 10.3390/pharmaceutics13060904

69. Cattaneo, D.; Perno, C.F.; Rizzardini, G. A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries. AIDS 2018, 32(17), 2625-2627. DOI:10.1097/QAD.0000000000002011

70. McConnachie, L.A.; Kinman, L.M.; Koehn, J.; Kraft, J.C.; Lane, S.; Lee, W.; Collier, A.C.; Ho, R.J. Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection. J. Pharm. Sci. 2018, 107(7), 1787-1790. DOI: 10.1016/j.xphs.2018.03.005

71. Koehn, J.; Iwamoto, J.F.; Kraft, J.C.; McConnachie, L.A.; Collier, A.C.; Ho, R.J. Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates. AIDS 2018, 32(17), 2463-2467. DOI: 10.1097/QAD.0000000000001969

72. Perazzolo, S.; Shen, D.D.; Scott, A.M.; Ho, R.J. Physiologically based pharmacokinetic model validated to enable predictions of multiple drugs in a long-acting drug-combination nano-particles (DCNP): confirmation with 3 HIV drugs, lopinavir, ritonavir, and tenofovir in DCNP products. J. Pharm. Sci. 2024, 113(6), 1653-1663. DOI: 10.1016/j.xphs.2024.02.018

73. Dominique, M.; Konstantin, H. (2016). Dosage form comprising lopinavir and ritonavir. U.S. Patent No. 9,370,578 B2. Washington, DC: U.S. Patent and Trademark Office.

74. Giardiello, M.N.; McDonald, T.O.; Owen, A.; Rannard, S.P. Compositions of lopinavir and ritonavir. International Publication number WO 2013/034927 A1.

75. Hampson, I.; Hampson, L. Lopinavir and ritonavir for the treatment of cervix disoprders. International Publication number WO 2019/224779 A1.

76. Pham, S.H; Choi, Y.; Choi, J. Stimuli-Responsive Nanomaterials for Application in Antitumor Therapy and Drug Delivery. Pharmaceutics 2020, 12(7), Art. No: 630. DOI: 10.3390/pharmaceutics12070630

77. Koh, H.B.; Kim, H.J.; Kang, S.W.; Yoo, T.H. Exosome-Based Drug Delivery: Translation from Bench to Clinic. Pharmaceutics 2023, 15(8), Art. No: 2042. DOI: 10.3390/pharmaceutics15082042

78. Asmamaw, M.; Zawdie, B. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics 2021, 15, 353-361. DOI: 10.2147/BTT.S326422

79. Kovarova, M.; Benhabbour, S.R.; Massud, I.; Spagnuolo, R.A.; Skinner, B.; Baker, C.E.; Sykes, C.; Mollan, K.R.; Kashuba, A. D. M.; García-Lerma, J. G.; Mumper, R. J.; Garcia, J. V. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun. 2018, 9(1), Art. No: 4156. DOI: 10.1038/s41467-018-06490-w

80. Khairkhah, N.; Namvar, A.; Bolhassani, A. Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections. Mol. Biotechnol. 2023, 65(9), 1387-1402. DOI: 10.1007/s12033-023-00679-1

81. Kevadiya, B.D.; Ottemann, B.; Mukadam, I. Z.; Castellanos, L.; Sikora, K.; Hilaire, J. R.; Machhi, J.; Herskovitz, J.; Soni, D.; Hasan, M.; Zhang, W.; Anandakumar, S.; Garrison, J.; McMillan, J.; Edagwa, B.; Mosley, R. L.; Vachet, R. W.; Gendelman, H. E. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics 2020, 10(2), 630-656. DOI: 10.7150/thno.39847

82. Jiang, J.; Ma, X.; Ouyang, D.; Williams, R. O. 3rd. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. Pharmaceutics 2022, 14(11), Art. No: 2257. DOI: 10.3390/pharmaceutics14112257.

83. Hama, R.; Ulziibayar, A.; Reinhardt, J.W.; Watanabe, T.; Kelly. J.; Shinoka. T. Recent Developments in Biopolymer-Based Hydrogels for Tissue Engineering Applications. Biomolecules 2023, 13(2), Art. No: 280. DOI: 10.3390/biom13020280

84. Hu, M.; Ge, X.; Chen, X.; Mao, W.; Qian, X.; Yuan, W. E. Micro/Nanorobot: A Promising Targeted Drug Delivery System. Pharmaceutics. 2020, 12(7), Art. No: 665. DOI: 10.3390/pharmaceutics12070665

85. Pan, X.; Veroniaina, H.; Su, N.; Sha, K.; Jiang, F.; Wu, Z.; Qi, X. Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian J. Pharm Sci. 2021, 16(6), 687-703. DOI: 10.1016/j.ajps.2021.05.003

Dr Singireddy Anand Reddy

anandreddy.pv@gmail.com

Dr Sobitha Rani

sobhitarani@gmail.com

Affiliation:

Associate Professor, Bhaskar Pharmacy College, Yenkapally, Moinabad-500075, Hyderabad, Telangana, India India

Bio Statement (e.g., department and rank)

Associate Professor, Bhaskar Pharmacy College, Yenkapally, Moinabad-500075, Hyderabad, Telangana, India